advocacy

D.C. Diagnosis Rachel Cohrs Zhang

STAT Plus: Dark money group runs ads on China biotech bill

First Opinion Hilary Hatch

Best time to deliver public health messages? When people are thinking about their health

First Opinion Antje M. Barreveld and Edin Randall

Treating chronic pain requires much more than medications

First Opinion Phyllis Arthur

A dose of reality on adult vaccinations

First Opinion Karen B. Lasater and K. Jane Muir

What nurses really want: sufficient staffing for patient care

First Opinion Ashley Ward and Jordan Clark

When heat threatens, use the wet bulb globe temperature to keep workers safe

Biotech Jason Mast

STAT Plus: Q&A with Jennifer Adair, researcher on a mission to increase global access to gene therapies

First Opinion Kimia Heydari and Romila Santra

Caring for young caregivers, a hidden population

First Opinion Sara Gorman, Scott C. Ratzan, and Kenneth H. Rabin

H5N1 communication has been strictly for the birds. Didn’t the federal government learn anything from Covid?

First Opinion Kay Redfield Jamison

People like me with bipolar disorder must help shape research and clinical care

First Opinion Jenn Kerfoot

Unseen battles: The harsh realities of veterans’ access to health care

Exclusive John Wilkerson

STAT Plus: Takeda is fourth big company to leave BIO since December

First Opinion Sionika Thayagabalu and Dominick Lemas

Medicaid should cover donor breast milk for vulnerable infants

First Opinion Catherine M. Klapperich

Needed for reproductive justice and autonomy: women in design

First Opinion Pam Kohl and Bill Kiser

Congress: Protect patients and enact the Nuclear Medicine Clarification Act

Politics Rachel Cohrs Zhang and John Wilkerson

STAT Plus: BIO’s top lobbyist exits, signaling reorganization

First Opinion Sydney Durrah

The influential adverse childhood experiences questionnaire should ask about gun violence

Health Katherine MacPhail

The latest twist in John Green’s anti-tuberculosis story: working with governments

First Opinion Thiago Arzua

Lessons for scientists from the All of Us Research Program backlash

First Opinion Elizabeth Weaver II and Kiana Jackson

Disabled scientists are often left out of academia. The NIH can help change that

First Opinion Joshua Mezrich

Too many donor organs go to waste. Here’s how to get them into the patients who need them

Politics Rachel Cohrs Zhang

STAT Plus: San Diego biotech Neurocrine Biosciences joins PhRMA

D.C. Diagnosis Rachel Cohrs Zhang

Colorado could cap payments for Amgen’s Enbrel

Health Nicholas Florko

Juul’s internal playbook opens a rare window into influence in Washington

The Readout Damian Garde

STAT Plus: Gilead sours on the ‘don’t eat me’ business

First Opinion Christopher M. Worsham and Anupam B. Jena

Clogged arteries: the unseen cost of road-blocking protests

D.C. Diagnosis Sarah Owermohle

STAT Plus: Health care negotiations on Capitol Hill are clear as mud

Business Brittany Trang

STAT Plus: Could private equity be the future of private practice? A new lobbying group thinks so

Special Report Sarah Owermohle

HHS’s Xavier Becerra, once an ‘invisible’ secretary, is racing to cement a clearer legacy